Home › Inflammatory Bowel Disease › NCT05003947

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for Crohn's Disease or Ulcerative Colitis

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Crohn's Disease or Ulcerative Colitis

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of Crohn's disease or Ulcerative Colitis
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Pre-menopausal women not using contraception
* Previous organ transplant
* Hypersensitivity to sulfur

About the study

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Crohn's Disease or Ulcerative Colitis

What is being tested

• cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 15 · Started: Jun 11, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05003947

Locations in the U.S.

Conditions

• Inflammatory Bowel Disease

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.